- US-listed companies
- Eton Pharmaceuticals, Inc.
- Income statement
Eton Pharmaceuticals, Inc. (ETON) Income statement
Market cap
$847.17M
P/E ratio
| 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Revenue | - | 1 | 0 | 22 | 21 | 32 | 39 |
| Revenue growth (%) | - | - | |||||
| Cost of revenue | - | 0 | 0 | - | 7 | 11 | 16 |
| Gross profit | - | 1 | -0 | 19 | 14 | 21 | 23 |
| Gross margin (%) | - | ||||||
| Research & development | 6 | 12 | 14 | 6 | 4 | 3 | 3 |
| Operating margin (%) | - | ||||||
| Operating expenses | 10 | 19 | 27 | 21 | 23 | 22 | 26 |
| Operating income | -10 | -19 | -27 | -1 | -8 | -1 | -3 |
| Income before tax | -13 | -18 | -28 | -2 | -9 | -1 | -4 |
| Pretax margin (%) | - | -1,910.3 | -71,717.9 | -9 | -42.4 | -2.2 | -9.8 |
| Provision for income taxes | - | - | - | - | - | 0 | 0 |
| Effective tax rate (%) | - | - | - | - | - | ||
| Net income | -13 | -18 | -28 | -2 | -9 | -1 | -4 |
| Net income margin (%) | - | ||||||
| Earnings per share | - | - | - | - | -0.36 | -0.04 | -0.15 |
| Diluted EPS | - | - | - | - | -0.36 | -0.04 | -0.15 |